Zura Bio (NASDAQ:ZURA) Trading 5.3% Higher – Here’s Why

Zura Bio Limited (NASDAQ:ZURA)’s share price rose 5.3% during trading on Friday . The company traded as high as $5.52 and last traded at $5.5280. 150,021 shares were traded during trading, a decline of 82% from the average daily volume of 851,443 shares. The stock had previously closed at $5.25.

Wall Street Analysts Forecast Growth

ZURA has been the topic of several research reports. Wall Street Zen cut shares of Zura Bio from a “sell” rating to a “strong sell” rating in a research report on Sunday, July 12th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Zura Bio in a research report on Monday, July 6th. William Blair initiated coverage on shares of Zura Bio in a research note on Wednesday, July 8th. They issued an “outperform” rating for the company. Wedbush restated an “outperform” rating and set a $15.00 target price on shares of Zura Bio in a research report on Wednesday, July 1st. Finally, Chardan Capital increased their price target on shares of Zura Bio from $10.00 to $11.00 and gave the company a “buy” rating in a report on Monday, March 23rd. One equities research analyst has rated the stock with a Strong Buy rating, four have issued a Buy rating, one has given a Hold rating and one has given a Sell rating to the stock. According to MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus price target of $10.75.

Zura Bio Stock Performance

The company has a market cap of $517.10 million, a PE ratio of -5.00 and a beta of -0.03. The company has a fifty day moving average of $4.49 and a two-hundred day moving average of $5.37.

Zura Bio (NASDAQ:ZURA) last posted its quarterly earnings data on Thursday, May 7th. The company reported ($0.22) EPS for the quarter, missing the consensus estimate of ($0.17) by ($0.05). On average, equities analysts forecast that Zura Bio Limited will post -0.76 EPS for the current year.

Hedge Funds Weigh In On Zura Bio

Several hedge funds have recently added to or reduced their stakes in ZURA. Bank of America Corp DE raised its position in Zura Bio by 31.9% in the 4th quarter. Bank of America Corp DE now owns 41,222 shares of the company’s stock worth $103,000 after purchasing an additional 9,966 shares during the period. AQR Capital Management LLC purchased a new position in shares of Zura Bio during the first quarter valued at approximately $72,000. JPMorgan Chase & Co. grew its stake in shares of Zura Bio by 78.7% during the second quarter. JPMorgan Chase & Co. now owns 4,659,951 shares of the company’s stock valued at $4,893,000 after buying an additional 2,052,732 shares during the last quarter. Jane Street Group LLC bought a new position in shares of Zura Bio during the second quarter valued at approximately $113,000. Finally, UBS Group AG raised its holdings in shares of Zura Bio by 878.3% in the third quarter. UBS Group AG now owns 305,329 shares of the company’s stock worth $1,322,000 after buying an additional 274,118 shares during the period. 61.14% of the stock is currently owned by institutional investors.

About Zura Bio

Zura Bio, Inc is a clinical-stage biotechnology company focused on the development of next-generation protein bioconjugates for therapeutic and diagnostic applications. Leveraging a proprietary platform for site-specific incorporation of non-canonical amino acids, the company aims to create highly targeted conjugates that improve drug delivery, enhance imaging contrast, and reduce off-target toxicity. Zura Bio’s technology is designed to streamline the manufacturing process by enabling precise attachment of payloads—such as cytotoxic drugs or imaging agents—to protein scaffolds without affecting their native structure or function.

The company’s research and development activities center on expanding its platform across multiple therapeutic areas, including oncology, immunology and rare diseases.